Thursday, July 31, 2014

"Scientists Test Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer"

One pioneering approach, discussed in a review article published this week in WIREs Nanomedicine and Nanobiotechnology, uses nanoparticles to jumpstart the body's ability to fight tumors. Nanoparticles are too small to imagine. One billion could fit on the head of a pin. This makes them stealthy enough to penetrate cancer cells with therapeutic agents such as antibodies, drugs, vaccine type viruses, or even metallic particles.
Though small, nanoparticles can pack large payloads of a variety of agents that have different effects that activate and strengthen the body's immune system response against tumors.

 

There is an expanding array of nanoparticle types being developed and tested for cancer therapy. They are primarily being used to package and deliver the current generation of cancer cell killing drugs and progress is being made in that effort.

"Our lab's approach differs from most in that we use nanoparticles to stimulate the immune system to attack tumors and there are a variety of potential ways that can be done," said Steve Fiering, PhD, Norris Cotton Cancer Center researcher and professor of Microbiology and Immunology, and of Genetics at the Geisel School of Medicine at Dartmouth. "Perhaps the most exciting potential of nanoparticles is that although very small, they can combine multiple therapeutic agents."

The immune therapy methods limit a tumor's ability to trick the immune system. It helps it to recognize the threat and equip it to effectively attack the tumor with more "soldier" cells. These approaches are still early in development in the laboratory or clinical trials.

"Now that efforts to stimulate anti-tumor immune responses are moving from the lab to the clinic, the potential for nanoparticles to be utilized to improve an immune-based therapy approach is attracting a lot of attention from both scientists and clinicians. And clinical usage does not appear too distant," said Fiering.

Fiering is testing the use of heat in combination with nanoparticles. An inactive metallic nanoparticle containing iron, silver, or gold is absorbed by a cancer cell. Then the nanoparticle is activated using magnetic energy, infrared light, or radio waves. The interaction creates heat that kills cancer cells. The heat, when precisely applied, can prompt the immune system to kill cancer cells that have not been heated. The key to this approach is minimizing healthy tissue damage while maximizing cancerous tumor destruction of the sort that improves recognition of the tumor by the immune system
Nanotechnology Now - Press Release: "Scientists Test Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer"

Wednesday, July 30, 2014

Nanotechnology Now - Press Release: "Nano-supercapacitors for electric cars"

Electric cars are very much welcomed in Norway and they are a common sight on the roads of the Scandinavian country - so much so that electric cars topped the list of new vehicle  registrations for the second time. This poses a stark contrast to the situation in Germany, where electric vehicles claim only a small portion of the market. Of the 43 million cars on the roads in Germany, only a mere 8000 are electric powered. The main factors discouraging motorists in Germany from switching to electric vehicles are the high investments cost,  their short driving ranges and the lack of charging stations. Another major obstacle en route to the mass acceptance of electric cars is the charging time involved. The minutes involved in refueling conventional cars are so many folds shorter that it makes the situation almost incomparable. However, the charging durations could be dramatically shortened with the inclusion of supercapacitors. These alternative energy storage devices are fast charging and can therefore better support the use of economical energy in electric cars. Taking traditional gasoline-powered vehicles for instance, the action of
braking converts the kinetic energy into heat which is dissipated and unused. Per contra, generators on electric vehicles are able to tap into the kinetic energy by converting it into electricity for further usage. This electricity often comes in jolts and requires storage devices that can withstand high amount of energy input within a short period of time. In this example, supercapacitors with their capability in capturing and storing this converted energy in an instant fits in the picture wholly. Unlike batteries that offer limited charging/discharging rates, supercapacitors require only seconds to charge and can feed the electric power back into the air-conditioning systems, defogger, radio, etc as required.
 
Rapid energy storage devices are distinguished by their energy and power density characteristics - in other words, the amount of electrical energy the device can deliver with respect to its mass and within a given period of time. Supercapacitors are known to possess high power density, whereby large amounts of electrical energy can be provided or captured within short durations, albeit at a short-coming of low energy density. The  amount of energy in which supercapacitors are able to store is generally about 10% that of electrochemical batteries (when the two devices of same weight are being compared). This is precisely where the challenge lies and what the "ElectroGraph" project is attempting to address. ElectroGraph is a project supported by the EU and its consortium consists of ten partners from both research institutes and industries. One of the main tasks of this project is to develop new types of supercapacitors with significantly improved energy storage capacities. As the project is approaches its closing phase in June, the project coordinator at Fraunhofer Institute for Manufacturing Engineering and Automation IPA in Stuttgart, Carsten Glanz explained the concept and approach taken en route to its successful conclusion: "during the storage process,  the electrical energy is stored as charged particles attached on the electrode material." "So to store more energy efficiently, we designed light weight electrodes with larger, usable surfaces."
  

Tuesday, July 29, 2014

The Nanomedicines Alliance: An Industry Perspective on Nanomedicines

The field of nanomedicines has expanded significantly in recent years in the breadth of compounds under development as   well          as  in  the  types  of  technology  that  are  being applied  to  generate nanomedicines.  The pathway to  licensure  of new  nanomedicines  is  sufficiently  well      defined by existing regulations and guidance.        The future of nanomedicines requires collaboration between industry and regulatory agencies to ensure that safe and effective nanomedicines emerge from this field.



Nanotechnology Now - Press Release: "Production of Toxic Gas Sensor Based on Nanorods"

Nanotechnology Now - Press Release: "Production of Toxic Gas Sensor Based on Nanorods"

Tuesday, July 22, 2014

Polysilsesquioxane Nanoparticles for Triggered Release of Cisplatin and Effective Cancer Chemoradiotherapy



An innovative strategy is to utilize nanoparticle (NP)chemotherapeutics in chemoradiation. Since the most commonly utilized chemotherapeutic with   radiotherapy is   cisplatin,  the  development  of a NP cisplatin for chemoradiotherapy has the  highest  potential  impact  on this treatment. Here,  we report the development of a NP comprised of polysilsesquioxane (PSQ) polymer crosslinked by a cisplatin prodrug (Cisplatin-PSQ) and its utilization in chemoradiotherapy using non-small cell lung cancer as a disease model.   Cisplatin-PSQ NP  has an  exceptionally high  loading of cisplatin. Cisplatin-PSQ NPs were        evaluated  in  chemoradiotherapy  in vitro and  in vivo.  They demonstrated significantly higher therapeutic  efficacy    when    compared to   cisplatin. These results suggest that the Cisplatin-PSQ NP holds potential for clinical translation in chemoradiotherapy.